NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Antibacterial Drugs: World Market Prospects 2013-2023
Report Details
Discover new trends, opportunities and revenue prospects for bacteria-killing medicines
Where's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities.
Our study lets you assess sales data and predictions for the world antibacterial drugs market, therapeutic submarkets, important products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.
Established and emerging bacteria-treating technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth.
Forecasts and other analyses to help you stay ahead in knowledge
That report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developmental trends (R&D). You gain 113 tables, 86 charts and two research interviews.
Is finding commercial data a challenge? With our study you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you find trends, innovations and opportunities for human medicine. You see what's happening, discovering possibilities.
There is rising need worldwide for drugs to treat bacterial infections. For those agents, our work helps you find business areas that will prosper, reducing the risk of your missing out.
The following sections show how you benefit from our new study of that antimicrobials field.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market for treating bacterial infections in human beings, you see forecasts to 2023 for these six submarkets:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other agents.
Our work shows you overall commercial prospects for generic and novel antibiotics.
Do you understand the changing market, knowledge needed to achieve maximum sales? Our report helps you identify potential and find opportunities for your business to prosper.
Likewise, our investigation discusses what stimulates and restrains business. In that work you find dynamics of the industry and assess its potential sales, seeing what drugs are likely to achieve the most success.
See revenue forecasts for 26 leading drugs
How will leading antibiotics perform to 2023 at world level? Our study forecasts sales of 26 products, including these brands:
• Augmentin
• Zyvox
• Avelox
• Cubicin
• Zosyn
• Cravit/Levaquin
• Merrem/Meropen
• Biaxin/Clarith
• Primaxin.
There you discover how high sales can go, to 2023, finding areas and years with highest predicted revenues and growth. Also, find how competitors compare - assess competition. You see what's happening, understanding trends, challenges and opportunities.
That study also divides its overall world revenue forecast into those for the main geographical markets.
What prospects for leading regions and countries?
In developed and developing countries - especially India and China - there are still many opportunities for developing, manufacturing and selling drugs to treat bacterial infections. You see opportunities for producers and sellers of those antimicrobial medicines.
Our analyses show you individual revenue forecasts to 2023 for eleven national markets and one regional block:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5) and a forecast for the EU
• Brazil, Russia, India and China (BRIC).
There you discover progress and outlooks. That way you assess the industry's future - hear about developments and find their significance.
Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, antibiotic product launches from 2013 to 2023 will change medical prescribing and the commercial landscape.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see developmental trends for these agents and others:
• Small molecule therapies
• Cephalosporins
• Oxazolidinones
• ß-Lactamase inhibition
• Macrolides
• Inhaled antibiotics
• MRSA-specific treatments.
In our work you assess innovations, hearing about developments and finding their significance. Discover progress.
See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing many issues.
What affects that antimicrobials field?
Our report discusses issues and events affecting that industry and market from 2013:
• Regulatory approvals and expanded indications
• Growth in emerging national and therapeutic markets
• Antibacterial drug resistance and restricting antibiotic use
• Challenge and opportunity in treating hospital-acquired infections (HAIs)
• Developments in antibacterial diagnostics
• Generic drugs and their competition to novel brands - patent challenges and expiries
• Combination therapy to aid product lifecycle management.
The work also discusses these aspects of the antibacterials field:
• Opportunities for biotechs, including developing of biological drug therapies
• Genomics in antibacterial drug development
• Public funding for research and antibiotic development
• Concerns over safety and marketing
• Oxazolidinone product launches with potential to invigorate the market
• Activity against MRSA stimulating revenue growth.
That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business.
Our investigation also lets you analyse the antibiotic drug industry's strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.
Leading companies and 2017 market value
What happens next? Our study predicts the overall world market for antibacterial drugs will reach $46bn in 2017, and expand further to 2023.
Our analyses show you what products and organisations hold greatest potential. Our work explores these leading companies:
• Pfizer
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Bayer
• Johnson & Johnson (J&J).
Our work also analyses these participants, and discusses other companies in the market:
• Cubist Pharmaceuticals
• AstraZeneca
• Taisho Toyama Pharmaceutical
• AbbVie
• Daiichi Sankyo.
In our study you find 175 organisations mentioned. Also, you read two interviews with authorities in that industry. See who shapes it, discovering what they think, do and say.
Prospects for R&D are encouraging, and from 2013 onwards there will arise opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.
Ten ways Antibacterial Drugs: World Market Prospects 2013-2023 helps you
In particular then, our investigation gives you the following knowledge:
• Revenues to 2023 for the world market for drugs to treat bacterial infections - you discover that industry's overall sales prospects
• Revenues to 2023 for 6 world-level submarkets - you investigate the potential of that industry's components, finding the most promising areas for investments and revenues
• Revenues to 2023 for 26 leading products - you find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, the EU, Brazil, Russia, India and China - you see national sales potentials, finding the best regions for revenues and growth
• Review of R&D for treating bacterial infectious diseases - you investigate progress in those research areas, finding technological and medical possibilities
• Discussions of leading companies - you hear about their strategies, capabilities, results and outlooks
• Interviews with leaders in the industry - you discover debates and opinions to help you stay ahead
• Competition and opportunities - you see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and firms seeking to enter the sector - you explore needs, practices and outlooks for future success.
You gain information found nowhere else
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Ordering now lets you discover predictions to 2023, finding information you need
Our investigation is for everyone needing analysis of the industry and market for antibacterial drugs. There you find data, trends, opportunities and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Outlook for the Antibacterial Drugs Market 2013-2023
1.2 Report Contents
1.3 Research and Analysis Methods
2. An Introduction to Bacterial Infections and Antibacterial Drugs
2.1 Bacterial Infections
2.1.1 How Do Bacteria Cause Infections?
2.1.2 How Are Bacteria Classified?
2.1.3 Types of Bacterial Infection
2.1.4 Leading Causes of Bacterial Infection
2.1.5 Incidence and Mortality Patterns for Common Bacterial Infections
2.2 Treating Bacterial Infections
2.2.1 A Brief History of Antibacterial Drug Development
2.2.2 Antibacterial Drug Action
2.2.3 Leading Classes of Antibacterial Drug
2.2.3.1 Cephalosporins
2.2.3.2 Penicillins
2.2.3.3 Carbapenems
2.2.3.4 Fluoroquinolones
2.2.3.5 Macrolides
2.2.4 Antibacterial Drug Resistance
3. Outlook for the Antibacterial Drugs Market 2013-2023
3.1 The World Antibacterial Drugs Market 2011-2012
3.1.1 Steady Revenue Growth for Antibacterial Drugs 2009-2012
3.1.2 What Are the Leading Sectors of the Market?
3.2 The World Antibacterial Drugs Market Forecast 2013-2023
3.2.1 What Will Drive Market Growth 2013-2023?
3.2.2 Drug Resistance and Generics to Restrain Growth to 2023
3.2.3 Changes to Submarket Shares 2013-2023
3.3 Leading Antibacterial Manufacturers 2013
3.3.1 Antibacterial Drugs is a Highly Fragmented Market
3.3.2 Limited Pipelines for Market Leaders
3.3.3 Outlook for the Top Ten Antibacterial Manufacturers 2013-2023
4. The Cephalosporin Submarket 2013-2023
4.1 The Cephalosporin Submarket 2011-2012
4.1.1 Most Cephalosporins Have Lost Patent Protection
4.2 The Cephalosporin Submarket Forecast 2013-2023
4.2.1 What Will Drive and Restrain Growth in the Cephalosporins Submarket?
4.2.2 Zinforo (Ceftaroline): The Newest Cephalosporin
4.2.3 Many Cephalosporins in the Pipeline
4.3 Rocephin
4.3.1 Opportunities for Continued Revenue
4.3.2 Revenue Forecast 2013-2023
4.4 Zinnat
4.4.1 Revenue Forecast 2013-2023
4.5 Flomox: Japan's Leading Cephalosporin
4.5.1 Patent Challenges 2009-2011
4.5.2 Revenue Forecast 2013-2023
4.6 Sulperazon
4.6.1 Revenue Growth in Emerging Markets 2013-2023
4.7 Meiact is a Popular Cephalosporin in Japan
4.7.1 Cefditoren in the US
4.7.2 Revenue Forecast 2013-2023
5. The Penicillin Submarket 2013-2023
5.1 The Penicillin Submarket 2011-2012
5.2 Steady Growth for the Penicillin Submarket 2013-2023
5.2.1 Submarket Drivers and Restraints 2013-2023
5.3 Augmentin: Off-Patent Blockbuster Revenues for a Decade
5.3.1 Augmentin Revenue Continues to Fall
5.3.2 Augmentin Recalled in Asian and Middle Eastern Markets 2011-2012
5.3.3 Faster Revenue Decline for Augmentin to 2023
5.4 Zosyn: An Effective Pneumonia Therapy
5.4.1 Zosyn Revenue: Rising in Japan, but Falling in the US
5.4.2 Patent Expiry and Revenue Extension for Pfizer
5.4.3 Revenue Forecast 2013-2023
5.5 Unasyn
5.5.1 Revenue Forecast 2013-2023
6. The Fluoroquinolone Submarket 2013-2023
6.1 Declining Revenue for Fluoroquinolones 2011-2012
6.1.1 Safety Concerns with Fluoroquinolones
6.2 The Fluoroquinolone Submarket Forecast 2013-2023
6.2.1 Avelox Patent Expiries to Restrain Growth
6.2.2 Fluoroquinolone Pipeline 2013
6.2.3 Fluoroquinolones as Inhaled Antibiotics
6.3 Avelox
6.3.1 Safety Concerns Affecting Revenue?
6.3.2 Patent Challenges
6.3.3 Will Avelox Remain as the Leading Fluoroquinolone to 2023?
6.4 Vigamox
6.4.1 Branded and Generic Challenges 2009-2012
6.4.2 Moxeza: A Next-Generation Form of Vigamox
6.4.3 Declining Revenue 2013-2023
6.5 Cravit and Levaquin
6.5.1 Generic Competition Affecting Revenue Worldwide
6.5.2 Lifecycle Management for Cravit and Levaquin
6.5.3 Continued Fall in Revenue 2013-2023
6.6 Cipro and Ciprodex: Two Formulations of Ciprofloxacin
6.6.1 Ciprodex: A Second Generation Ophthalmic Antibiotic
6.6.2 Cipro Revenue Forecast 2013-2023: Continued Generic Erosion
6.6.3 Ciprodex: Revenue Forecast 2013-2023
7. The Macrolide Submarket 2013-2023
7.1 The Macrolide Submarket 2011-2012
7.2 Growth for the Macrolide Market 2013-2023
7.2.1 Growth to be Driven by Uptake of Dificid
7.2.2 There Are Few New Macrolides in the Pipeline
7.3 Biaxin and Clarith
7.3.1 Falling Revenue for Biaxin and Clarith 2010-2012
7.3.2 Lifecycle Management for Continued Market Presence
7.3.3 Declining Revenue 2013-2023
7.4 Zithromax/Zmax
7.4.1 Concerns Over Safety and Marketing in the US
7.4.2 Effectiveness in Drug-Resistant Strains
7.4.3 Revenue Forecast 2013-2023
7.5 Dalacin
7.5.1 Revenue Decline 2013-2023
7.6 Dificid: The First New CDAD Therapy for 25 Years
7.6.1 Rapid Uptake Slowed by High Cost
7.6.2 New Approvals and Expanded Indications
7.6.3 Revenue Forecast 2013-2023
8. The Carbapenem Submarket 2013-2023
8.1 The Carbapenem Submarket 2011-2012
8.1.1 Rising Prevalence of Carbapenemases and ?-Lactamases
8.2 The Carbapenem Submarket Forecast 2013-2023
8.2.1 No New Carbapenems in Late-Stage Trials
8.3 Merrem and Meropen: The Leading Carbapenem
8.3.1 Generics Affecting Revenue Worldwide
8.3.2 Revenue Forecast 2013-2023
8.4 Primaxin
8.4.1 Declining Demand for Primaxin 2010-2012
8.4.2 Combination Therapy for Lifecycle Management
8.4.3 Revenue Forecast 2013-2023
8.5 Invanz
8.5.1 Revenue Forecast
8.6 Doribax is the Newest Carbapenem
8.6.1 Doribax in HAP and VAP
8.6.2 Lifecycle Management in Japan and the Rest of the World
8.6.3 Strong Revenue Growth 2013-2023
9. Other Leading Antibacterial Drug Sectors 2013-2023
9.1 The Other Sectors Submarket 2011-2012
9.2 Strong Growth for Other Sectors 2013-2023
9.2.1 New Oxazolidinones Will Drive Growth
9.2.2 New Drug Classes to Drive Submarket Growth to 2023
9.3 Zyvox: The World's First Oxazolidinone
9.3.1 Activity Against MRSA Driving Revenue Growth
9.3.2 Promise in Tuberculosis and Anthrax
9.3.3 Strong Novel and Generic Competition 2013-2023
9.4 Cubicin
9.4.1 Revenue Boosted by Approvals Worldwide
9.4.2 Patent Challenges and Settlements to Ensure Market Exclusivity
9.4.3 Blockbuster Potential in the US 2013-2023
9.5 Solodyn: The Leading Dermatological Drug in the US
9.5.1 Generic Competition and Lifecycle Management
9.5.2 Solodyn Revenue Forecast
9.6 Tygacil
9.6.1 Concerns Limiting Revenue Potential
9.6.2 Steady Revenue Growth and Generic Competition 2013-2023
9.7 TOBI and TIP: Novartis' Inhaled Tobramycin
9.7.1 Revenue Performance 2011-2012
9.7.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.7.3 TOBI and TIP Revenue Forecast 2013-2023
9.8 Vibativ: What Potential for the Newest Lipopeptide?
9.8.1 Astellas Ends its Collaboration with Theravance
9.8.2 Will Vibativ be Approved for HAP in the US?
10. Leading National Markets for Antibacterial Drugs 2013-2023
10.1 Leading National Markets for Antibacterial Drugs 2011-2012
10.1.1 Growth for Leading National Markets 2013-2023
10.1.2 How Will National Market Shares Change Between 2013 and 2023?
10.2 The US is the Largest Market for Antibacterial Drugs
10.2.1 The US: Antibacterial Drug Market Forecast 2013-2023
10.3 Antibacterial Drugs in the EU 2013-2023
10.3.1 Leading EU Markets for Antibacterial Drugs 2011-2012
10.3.2 Action to Encourage Antibacterial Drug Development in the EU 2011-2012
10.3.3 The EU: Leading National Market Forecasts 2013-2023
10.3.4 France: Aiming to Cut a Quarter of Antibacterial Use by 2016
10.3.5 High Resistance Rates in Italy
10.3.6 Germany: Fighting Antibacterial Resistance at a National and Regional Level
10.3.7 Spain
10.3.8 UK-Based Companies Are Investing in Antibacterial Drug Development
10.4 China: The Second Largest Market for Antibacterial Drugs
10.4.1 Development of New Antibiotics in China
10.4.2 Chinese Market Forecast 2013-2023
10.5 Japan
10.5.1 Japanese Market Forecast 2013-2023
10.6 The Indian Market: Growth Driven by Ease of Availability
10.6.1 Restricting Antibiotic Use in India
10.6.2 Indian Market Forecast 2013-2023
10.7 Cutting Antibiotic Use in Brazil
10.7.1 Brazilian Market to Be Driven by Drug Resistance and TB
10.8 Russia Has Lower Antibacterial Drug Use than Other Emerging Markets
11. Antibacterial Drug R&D Pipeline 2013
11.1 Gram-Positive vs. Gram-Negative
11.2 A Pipeline Dominated by Small Molecule Drugs
11.3 Ceftobiprole: Submitted to the EMA for a Second Time
11.4 Phase III Candidates
11.4.1 CAZ-AVI (Ceftazidime/Avibactam)
11.4.2 CB-315 is a Second Generation Lipopeptide
11.4.3 CEM-101 is the Only Macrolide in Late-Stage Trials
11.4.4 CXA-201
11.4.5 Will Dalbavancin be the Next Pipeline Antibiotic to Reach the US Market?
11.4.6 Finafloxacin for Ear Infections
11.4.7 Nuvocid (Oritavancin)
11.4.8 Tedizolid Will Be a Key Market Driver for Oxazolidinones to 2023
11.5 Leading Phase II Antibacterial Drug Candidates
11.5.1 ACHN-490 is Approaching Phase III for UTIs
11.5.2 AZD5847: An Oxazolidinone for TB
11.5.3 Cadazolid: A Combination of Oxazolidinone and Quinolone
11.5.4 CEF104
11.5.5 Delafloxacin
11.5.6 JNJ-Q2
11.5.7 MK-7655 is a Next Generation ?-Lactamase Inhibitor
11.5.8 Omadacycline
11.5.9 Radezolid
11.5.10 Pfizer has a Second Oxazolidinone in Development
11.5.11 Solithromycin: The Only Macrolide in Mid-Stage Development
11.5.12 TD-1792
11.5.13 TP-434
11.6 Novel Drug Classes and Mechanisms of Action
11.6.1 AFN-1252: A Highly Specific Antibacterial Drug Candidate
11.6.2 BC-3781
11.6.3 Brilacidin: Mimicking Natural Defence Systems
11.7 Inhaled Antibiotics
11.7.1 Cayston: Competition in the Pipeline
11.7.2 Aeroquin
11.7.3 Bayer is Developing Ciprofloxacin for Inhalation
11.7.4 NKTR-061: Bayer's Second Inhaled Antibiotic
11.7.5 Pulmaquin: A Second Ciprofloxacin Candidate
11.7.6 AeroVanc Targets MRSA Infections
12. Antibacterial Drugs: Industry Trends 2013-2023
12.1 Strengths and Weaknesses in the Antibacterial Drugs Market 2013
12.2 Opportunities and Threats in the Antibacterial Drugs Market 2013-2023
12.3 Antibacterial Drug Market: STEP Analysis
12.3.1 Social Factors
12.3.2 Technological Developments
12.3.3 Economic Pressures
12.3.4 Political Issues
12.4 Trends in Drug Development 2013-2023
12.4.1 Targeting Drug-Resistant Bacteria
12.4.2 Resistance in Gonorrhoea is Rising
12.4.3 Drug-Resistant TB is a Serious Issue in Emerging Markets
12.4.3.1 Sirturo (Bedaquiline): A New TB Therapy
12.4.4 Biologics - an Emerging Opportunity for Fighting Bacterial Infections
12.4.4.1 MK-3415A: An Antibody Therapy Against C. Difficile
12.4.4.2 SAR279356
12.4.4.3 Kenta Biotech: Targeting P. aeruginosa and S. aureus
12.4.5 Vaccines for Preventing Bacterial Infections
12.4.6 Drug Reformulation and Lifecycle Management
12.5 Big Pharma and Antibacterial Drug Development
12.5.1 Revenue Growth Post-Launch for Antibacterial Drugs
12.5.2 The Opportunity for Small Biotechs
12.6 The Role of Government and Industry Associations in Antibacterial Drug Development
12.6.1 A Challenging Regulatory Environment
12.6.1.1 Regulatory Updates in the EU 2012
12.6.2 Incentivising Antibacterial Drug Development
12.6.2.1 GAIN: Post-Development Incentives in the US
12.6.3 Public Funding for Antibacterial Drug Development
12.6.3.1 IMI: Public-Private Collaboration in the EU
12.6.3.2 Increased Development Funding in the US for Antibiotics
12.7 Challenges in Development of Antibacterial Drugs
12.7.1 Differing Clinical Trial Requirements in Leading Markets
12.7.2 Non-Inferiority Trials Are Necessary but Challenging
12.7.3 The Role of Genomics in Antibacterial Drug Development
12.8 The Challenge and Opportunity of Hospital-Acquired Infections
12.8.1 Innovative Solutions for Treating HAIs
12.8.1.1 Developing New Antibacterial Diagnostics
12.8.2 Strategies for Preventing HAIs
12.8.2.1 Developments in Materials Used for Hospital Equipment
12.8.2.2 New Technologies for Hospital Cleaning
12.9 Rising Bacterial Resistance
12.9.1 New Resistant Strains Are Emerging
12.9.2 Drug Use May Be Restricted to Prevent Resistance Developing
13. Research Interviews
13.1 Rob Neville, Co-Founder and CEO, Savara Pharmaceuticals
13.1.1 Savara Pharmaceuticals
13.1.2 The Interest in Inhaled Antibiotic Development
13.1.3 Challenges in Developing Inhaled Antibiotics
13.1.4 Potential Uses for Inhaled Antibiotics
13.1.4.1 The Potential for AeroVanc
13.1.5 Lower Risk of Antibacterial Resistance
13.2 Affinium Pharmaceuticals
13.2.1 Company Profile
13.2.2 Opportunities for Specific Antibacterial Drugs
13.2.3 Challenges in Developing Specific Antibacterial Agents
13.2.4 Future Development Targets for Antibacterial Drugs
13.2.4.1 Using Affinium's Approach for Gram-Negative Infections
14. Conclusions from Our Study
14.1 Growth in the Antibacterial Drugs Market 2013-2023
14.2 Outlook for Leading Products 2013
14.2.1 Are There Enough New Drugs in the Antibacterial Pipeline?
14.3 Main Trends in the Antibacterial Drug Market 2013-2023
List of Tables
Table 1.1 Currency Exchange Rates, 2012
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 Common Bacterial Infections and Their Causes, 2013
Table 2.2 Overview of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Disease Death, 2008
Table 2.4 Mechanisms of Action for Antibacterial Drugs, 2013
Table 3.1 Antibacterial Drugs Market, 2009-2012
Table 3.2 Antibacterial Drugs Market by Sector, 2011
Table 3.3 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.4 Antibacterial Drugs Market: Submarket Shares, 2011-2023
Table 3.5 Leading Antibacterial Drug Manufacturers: Revenues and Market Shares, 2011-2012
Table 4.1 Leading Cephalosporin Drugs: Key Facts, 2013
Table 4.2 Cephalosporin Submarket by Drug: Revenues and Market Shares, 2011
Table 4.3 Cephalosporin Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 4.4 Cephalosporin Submarket: Shares for Leading Drugs, 2011-2023
Table 4.5 Rocephin: Revenue by Quarter, 2011-2012
Table 4.6 Rocephin: Revenue Forecast, 2012-2023
Table 4.7 Zinnat: Revenue Forecast, 2012-2023
Table 4.8 Flomox: Revenue Forecast, 2012-2023
Table 4.9 Sulperazon: Revenue, 2009-2012
Table 4.10 Sulperazon: Revenue Forecast, 2012-2023
Table 4.11 Meiact/Spectracef: Revenue Forecast, 2012-2023
Table 5.1 Leading Penicillin Drugs: Key Facts, 2013
Table 5.2 Penicillin Submarket by Drug: Revenues and Market Shares, 2011
Table 5.3 Penicillin Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 5.4 Penicillin Submarket: Shares for Leading Drugs, 2011-2023
Table 5.5 Augmentin: Revenue, 2009-2012
Table 5.6 Augmentin: Revenue Forecast, 2012-2023
Table 5.7 Zosyn: Revenue, 2009-2012
Table 5.8 Zosyn: Revenue Forecast, 2012-2023
Table 5.9 Unasyn: Revenue, 2009-2012
Table 5.10 Unasyn: Revenue Forecast, 2012-2023
Table 6.1 Leading Fluoroquinolone Drugs: Key Facts, 2013
Table 6.2 Fluoroquinolone Submarket by Drug: Revenues and Market Shares, 2011
Table 6.3 Fluoroquinolone Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 6.4 Fluoroquinolone Submarket: Shares for Leading Drugs, 2011-2023
Table 6.5 Patent Expiries for Avelox in Major Markets, 2013-2015
Table 6.6 Avelox: Revenue by Company, Q1-Q3 2011-2012
Table 6.7 Avelox: Revenue Forecast, 2012-2023
Table 6.8 Vigamox: Revenue Forecast, 2012-2023
Table 6.9 Cravit and Levaquin: Revenues, 2009-2012
Table 6.10 Cravit and Levaquin: Revenue Forecast, 2012-2023
Table 6.11 Cipro: Revenue, 2009-2012
Table 6.12 Cipro: Revenue Forecast, 2012-2023
Table 6.13 Ciprodex: Revenue Forecast, 2012-2023
Table 7.1 Leading Macrolide Drugs: Key Facts, 2013
Table 7.2 Macrolide Submarket by Drug: Revenues and Market Shares, 2011
Table 7.3 Macrolide Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 7.4 Macrolide Submarket: Shares for Leading Drugs, 2011-2023
Table 7.5 Biaxin and Clarith: Revenues, 2009-2012
Table 7.6 Biaxin and Clarith: Revenue Forecast, 2012-2023
Table 7.7 Zithromax/Zmax: Revenue, 2009-2012
Table 7.8 Zithromax/Zmax: Revenue Forecast, 2012-2023
Table 7.9 Dalacin: Revenue, 2009-2012
Table 7.10 Dalacin: Revenue Forecast, 2012-2023
Table 7.11 Dificid: US Revenue by Quarter, 2011-2012
Table 7.12 Dificid: Revenue Forecast, 2012-2023
Table 8.1 Leading Carbapenem Drugs: Key Facts, 2013
Table 8.2 Carbapenem Submarket by Drug: Revenues and Market Shares, 2011
Table 8.3 Carbapenem Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 8.4 Carbapenem Submarket: Shares for Leading Drugs, 2011-2023
Table 8.5 Merrem and Meropen: Revenue by Brand, 2009-2012
Table 8.6 Merrem and Meropen: Revenue Forecast, 2012-2023
Table 8.7 Primaxin: Revenue, 2009-2012
Table 8.8 Primaxin: Revenue Forecast, 2012-2023
Table 8.9 Invanz: Revenue, 2009-2012
Table 8.10 Invanz: Revenue Forecast, 2012-2023
Table 8.11 Doribax: Revenue Forecast, 2012-2023
Table 9.1 Other Leading Antibacterial Drugs: Key Facts, 2013
Table 9.2 Other Antibacterial Drugs Submarket by Drug: Revenues and Market Shares, 2011
Table 9.3 Other Antibacterial Drugs Submarket and Leading Drugs: Revenue Forecasts, 2011-2023
Table 9.4 Other Antibacterial Drugs Submarket: Shares for Leading Drugs, 2011-2023
Table 9.5 Selected Oxazolidinones in Development, 2013
Table 9.6 Zyvox: Revenue, 2009-2012
Table 9.7 Zyvox: Revenue Forecast, 2012-2023
Table 9.8 Cubicin: US Revenue, 2008-2012
Table 9.9 Cubicin: US Revenue Forecast, 2012-2023
Table 9.10 Solodyn: Revenue Forecast, 2012-2023
Table 9.11 Tygacil: Revenue, 2009-2012
Table 9.12 Tygacil: Revenue Forecast, 2012-2023
Table 9.13 TOBI and TIP: Revenue, 2009-2012
Table 9.14 TOBI and TIP: Revenue Forecast, 2012-2023
Table 10.1 Antibacterial Drugs Market by Country: Revenues and Market Shares, 2011
Table 10.2 Antibacterial Drugs Market: Revenue Forecasts by Country, 2011-2023
Table 10.3 Antibacterial Drugs Market: National Market Shares, 2011-2023
Table 10.4 US Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.5 EU Antibacterial Drugs Market by Country, 2011
Table 10.6 EU Antibacterial Drugs Market: Revenue Forecasts by Country, 2011-2023
Table 10.7 French Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.8 Italian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.9 German Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.10 Spanish Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.11 Selected UK Pharmaceutical Companies Developing Novel Antibacterial Drugs, 2013
Table 10.12 UK Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.13 Chinese Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.14 Japanese Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.15 Indian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.16 Brazilian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 10.17 Russian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Table 11.1 Selected Small Molecule Antibacterial Drug Pipeline Candidates, 2013
Table 11.2 Comparison of Clinical Pipelines for Leading Pharmaceutical Sectors, 2010-2012
Table 11.3 Inhaled Antibiotics: Selected Clinical Candidates, 2013
Table 12.1 Antibacterial Drugs Market: Strengths and Weaknesses, 2012-2013
Table 12.2 Antibacterial Drugs Market: Opportunities and Threats, 2013-2023
Table 12.3 Antibacterial Drugs Market: STEP Analysis, 2013-2023
Table 12.4 Antibacterial Drugs: Selected Biological Clinical Candidates, 2013
Table 12.5 Big Pharma Antibacterial Pipeline: Statistical Overview, 2013
Table 12.6 Revenue Growth Potential for Antibacterial Drugs, 2013
Table 12.7 Drugs Granted IDP Status in the US, 2012-2013
Table 12.8 Selected NIAID Funding for Antibacterial Drug Development, 2010-2012
Table 12.9 Selected BARDA Funding for Antibacterial Drug Development, 2010-2012
Table 12.10 Proposed Four-Tier Clinical Development Guideline
Table 14.1 Antibacterial Drugs Market by Sector, 2011, 2017 and 2023
List of Figures
Figure 2.1 Leading Causes of Infectious Disease Death, 2008
Figure 2.2 Key Developments in the Antibacterial Drugs Market, 1940-2010
Figure 2.3 Structures for ?-Lactam Based Antibiotic Classes
Figure 3.1 Antibacterial Drugs Market, 2009-2012
Figure 3.2 Antibacterial Drugs Market by Sector, 2011
Figure 3.3 Antibacterial Drugs Market Forecast, 2012-2023
Figure 3.4 Antibacterial Drugs Market by Sector, 2017
Figure 3.5 Antibacterial Drugs Market by Sector, 2023
Figure 3.6 Antibacterial Drugs Market: Shares by Company, 2011
Figure 4.1 Cephalosporin Submarket by Drug: Shares, 2011
Figure 4.2 Cephalosporin Submarket: Revenue Forecast, 2012-2023
Figure 4.3 Rocephin: Revenue, 2011-2012
Figure 4.4 Rocephin: Revenue Forecast, 2012-2023
Figure 4.5 Zinnat: Revenue Forecast, 2012-2023
Figure 4.6 Flomox: Revenue Forecast, 2012-2023
Figure 4.7 Sulperazon: Revenue, 2009-2012
Figure 4.8 Sulperazon: Revenue Forecast, 2012-2023
Figure 4.9 Meiact/Spectracef: Revenue Forecast, 2012-2023
Figure 5.1 Penicillin Submarket by Drug: Shares, 2011
Figure 5.2 Penicillin Submarket: Revenue Forecast, 2012-2023
Figure 5.3 Augmentin: Revenue, 2009-2012
Figure 5.4 Augmentin: Revenue Forecast, 2012-2023
Figure 5.5 Zosyn: Revenue, 2009-2012
Figure 5.6 Zosyn: Revenue Forecast, 2012-2023
Figure 5.7 Unasyn: Revenue, 2009-2012
Figure 5.8 Unasyn: Revenue Forecast, 2012-2023
Figure 6.1 Fluoroquinolone Submarket by Drug: Shares, 2011
Figure 6.2 Fluoroquinolone Submarket: Revenue Forecast, 2012-2023
Figure 6.3 Avelox: Revenue, Q1-Q3 2011-2012
Figure 6.4 Avelox: Revenue Forecast, 2012-2023
Figure 6.5 Vigamox: Revenue Forecast, 2012-2023
Figure 6.6 Cravit and Levaquin: Revenues, 2009-2012
Figure 6.7 Cravit and Levaquin: Revenue Forecast, 2012-2023
Figure 6.8 Cipro: Revenue, 2009-2012
Figure 6.9 Cipro: Revenue Forecast, 2012-2023
Figure 6.10 Ciprodex: Revenue Forecast, 2012-2023
Figure 7.1 Macrolide Submarket by Drug: Shares, 2011
Figure 7.2 Macrolide Submarket: Revenue Forecast, 2012-2023
Figure 7.3 Biaxin and Clarith: Revenues, 2009-2012
Figure 7.4 Biaxin and Clarith: Revenue Forecast, 2012-2023
Figure 7.5 Zithromax/Zmax: Revenue, 2009-2012
Figure 7.6 Zithromax/Zmax: Revenue Forecast, 2012-2023
Figure 7.7 Dalacin: Revenue, 2009-2012
Figure 7.8 Dalacin: Revenue Forecast, 2012-2023
Figure 7.9 Dificid: US Revenue, 2011-2012
Figure 7.10 Dificid: Revenue Forecast, 2012-2023
Figure 8.1 Carbapenem Submarket by Drug: Shares, 2011
Figure 8.2 Carbapenem Submarket: Revenue Forecast, 2012-2023
Figure 8.3 Merrem and Meropen: Revenue by Brand, 2009-2012
Figure 8.4 Merrem and Meropen: Revenue Forecast, 2012-2023
Figure 8.5 Primaxin: Revenue, 2009-2012
Figure 8.6 Primaxin: Revenue Forecast, 2012-2023
Figure 8.7 Invanz: Revenue, 2009-2012
Figure 8.8 Invanz: Revenue Forecast, 2012-2023
Figure 8.9 Doribax: Revenue Forecast, 2012-2023
Figure 9.1 Other Antibacterial Drugs Submarket by Drug: Shares, 2011
Figure 9.2 Other Antibacterial Drugs Submarket: Revenue Forecast, 2012-2023
Figure 9.3 Zyvox: Revenue, 2009-2012
Figure 9.4 Zyvox: Revenue Forecast, 2012-2023
Figure 9.5 Cubicin: US Revenue, 2008-2012
Figure 9.6 Cubicin: US Revenue Forecast, 2012-2023
Figure 9.7 Solodyn: Revenue Forecast, 2012-2023
Figure 9.8 Tygacil: Revenue, 2009-2012
Figure 9.9 Tygacil: Revenue Forecast, 2012-2023
Figure 9.10 TOBI and TIP: Revenue, 2009-2012
Figure 9.11 TOBI and TIP: Revenue Forecast, 2012-2023
Figure 10.1 Antibacterial Drugs Market by Country: Shares, 2011
Figure 10.2 Antibacterial Drugs Market by Country: Shares, 2017
Figure 10.3 Antibacterial Drugs Market by Country: Shares, 2023
Figure 10.4 US Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.5 EU Antibacterial Drugs Market by Country: Shares, 2011
Figure 10.6 EU Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.7 French Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.8 Italian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.10 Spanish Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.11 UK Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.12 Chinese Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.13 Japanese Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.14 Indian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.15 Brazilian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 10.16 Russian Antibacterial Drugs Market: Revenue Forecast, 2012-2023
Figure 12.1 Selected TB Pipeline, 2013
Figure 12.2 Big Pharma Antibacterial Pipeline Statistics, 2013
Figure 12.3 Selected Strategies for Preventing HAIs, 2013
Figure 14.1 Antibacterial Drugs Market, 2011, 2017 and 2023
Companies Listed
AbbVie
Achaogen
Actavis
Actelion Pharmaceuticals
Advanced Life Sciences
Aeras
Affinium Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agentschap voor Innovatie door Wetenschap en Technologie (IWT) [Belgium]
Alcon Laboratories (part of Novartis)
Alkem Laboratories
Allergan
Alliance for the Prudent Use of Antibacterials (APUA)
Alopexx Pharmaceuticals
Apotex
APP Pharmaceuticals (part of Fresenius Kabi)
Aptalis Pharma (formerly Axcan)
Aquapharm Biodiscovery
Aradigm
Arsanis
Ascend Therapeutics
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals (part of Teva)
Basilea Pharmaceutica
Bausch & Lomb
Bayer
Biomedical Advanced Research and Development Authority (BARDA) [US]
Calixa Therapeutics (part of Cubist)
Cempra Pharmaceuticals
Centers for Disease Control and Prevention (CDC) [US]
Centers for Medicare and Medicaid Services (CMS) [US]
Cepheid
Chiron (part of Novartis)
Cornerstone Therapeutics
Corus Pharma (part of Gilead Sciences)
Cubist Pharmaceuticals
Curetis
Daiichi Sankyo
Dainippon Sumitomo Pharma
Destiny Pharma
Discuva
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP)
Enanta Pharmaceuticals
EnZtek Diagnostics
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Parliament
Evolva Holding
Food and Drug Administration (US FDA)
Forest Laboratories
Furiex Pharmaceuticals
Galapagos
Gilead Sciences
GlycoVaxyn
GSK
Guangdong BeiKang (part of AstraZeneca)
Harvard Medical School
Hikma Farmaceutica
Hospira
Infectex
Infectious Disease Society of America (IDSA)
Innocell
Innovative Medicines Initiative (IMI) [EU]
Insmed
Institut National de la Santé et de la Recherche Médicale (INSERM) [France]
Intercell
Isis Pharmaceuticals
Itochu Chemical Frontier
J&J
Janssen Pharmaceutica (part of J&J)
Japan Patent Office (JPO)
KaloBios Pharmaceuticals
Kenta Biotech
Lupin Pharmaceuticals
Mayo Clinic
Medical University of South Carolina
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Medicis (part of Valeant)
Medison Pharma
Medsintez
Meiji Seika Pharma
Merck & Co.
MerLion Pharmaceuticals
Michigan State University
MicuRx Pharmaceuticals
Ministry of Health [China]
Ministry of Health [UAE]
Ministry of Health and Family Welfare [India]
Ministry of Health Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mpex Pharmaceuticals (part of Aptalis)
Mylan
Mylan Seiyaku (part of Mylan)
Nabriva Therapeutics
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute of Allergy and Infectious Diseases (NIAID) [US]
National Institutes for Health (NIH) [US]
Nektar Therapeutics
Nichi-Iko Pharmaceutical
Nipro Pharma
Novacta Biosystems
NovaDigm Therapeutics
Novartis
Novexel (part of AstraZeneca)
Optimer Biotechnology (part of Optimer Pharmaceuticals)
Optimer Pharmaceuticals
Orchid Chemicals & Pharmaceuticals
Ortho-McNeil Pharmaceutical (part of J&J)
Otsuka Pharmaceutical
Paratek Pharmaceuticals
Peninsula Pharmaceuticals (part of J&J)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia (part of Pfizer)
Phico Therapeutics
Pliva (part of Teva)
PolyMedix
Procarta Biosystems
Ranbaxy Laboratories (part of Daiichi Sankyo)
Redx Pharma
Rib-X Pharmaceuticals
Rising Pharmaceuticals
Roche
Sandoz (part of Novartis)
Sanofi
Savara Pharmaceuticals
Sawai Pharmaceutical
Schering-Plough (part of Merck & Co.)
Scottish Medicines Consortium (SMC)
Sequella
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shionogi
Specialised Therapeutics Australia
State Food and Drug Administration (SFDA) [China]
Stop TB Partnership
Sunovion Pharmaceuticals
Taisho Toyama Pharmaceutical
Taiyo Yakuhin
Takeda Pharmaceutical Company
TAP Holdings
Targanta Therapeutics (part of The Medicines Company)
TB Alliance
Tedec-Meiji Farma (part of Meiji Seika Pharma)
Tetraphase Pharmaceuticals
Teva Pharmaceuticals
Texas Emerging Technology Fund
The Medicines Company
Theravance
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
Transave (part of Insmed)
Trius Therapeutics
UNITAID
University of Birmingham [US]
University of Michigan
US Department of Health and Human Services (HHS)
US Food and Drug Administration (FDA)
US Patent and Trademark Office
Valeant Pharmaceuticals
Vansen Pharma
Vertex Pharmaceuticals
Vicuron Pharmaceuticals (part of Durata Therapeutics)
ViroPharma
Wockhardt
World Health Organization (WHO)
Wyeth (part of Pfizer)
Xenex
Zuellig Pharma
To order this report:
Drug_and_Medication Industry: Antibacterial Drugs: World Market Prospects 2013-2023
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article